/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Viracta Therapeutics, Inc. ( Viracta or the Company ) is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. The association of viruses and cancer has been well characterized, and Viracta s lead program is focused on cancers associated with the Epstein-Barr virus ( EBV ).
ROIC dropped from -42.95% to -61.55%, capital efficiency is deteriorating. Negative free cash flow of -$40M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$43M
▼ -3.8% YoY
Op. Margin
—
ROIC
-89.58%
▼ -18.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$35M
▼ -12.8% YoY
Op. Cash Flow (TTM)
-$35M
▼ -12.5% YoY
Net Debt
$13M
Cash & Equiv.
$21M
5Y CAGR: -47.7%
Continue Research
SourceComputed from the 10-Q filed 13 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.